KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.

Ning Li, Wei Ou, Chao Cheng, Jian You, Lin Yang, Feng-Xia Chen, Yi Liang, Zhixiong Yang, Bao-Xiao Wang, Zeng-Hao Chang, Yao-Bin Lin, Weixiong Yang, Feng Xu, Guanggui Ding, Xian-Shan Chen, Ronggui Hu, Shujun Li, Hao Jiang, Xin-Xin Hu, Hao Long, Si-Yu Wang

Signal Transduct Target Ther 10(1) 273

PMID40866342
PMCIDPMC12391381
DOI10.1038/s41392-025-02358-w
发表日期2025-08-27
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

The efficacy, safety and ideal treatment duration of an adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with resected EGFR-mutated non-small-cell lung cancer (NSCLC) were not known until 2014, when this study was initiated. In this phase 3 ICTAN trial (GASTO1002, NCT01996098), patients with completely resected, EGFR-mutated, stage II-IIIA NSCLC after adjuvant chemotherapy were assigned in a 1:1:1 ratio to receive icotinib (125 mg, three times daily) for 12 months, to receive icotinib for 6 months, or to undergo observation. The primary endpoint was disease-free survival (DFS). This trial was terminated early. A total of 251 patients were randomized. Adjuvant icotinib for 12 months significantly improved DFS (hazard ratio [HR]: 0.40, 95% confidence interval [CI], 0.27-0.61; P < 0.001) and overall survival (OS; HR: 0.55, 95% CI, 0.32-0.96; P = 0.032) compared with observation. Adjuvant icotinib of 6 months also significantly improved DFS (HR: 0.41, 95% CI, 0.27-0.62; P < 0.001) and OS (HR: 0.56, 95% CI, 0.32-0.98; P = 0.038) compared with observation. Adjuvant icotinib for 12 months did not improve DFS (HR: 0.97; P = 0.89) or OS (HR: 1.00; P = 0.99) compared with 6 months of this drug. Rates of adverse events of grade 3 or higher were 8.3%, 6.0% and 2.4% for the 12-month icotinib, 6-month icotinib, and observation groups, respectively. Adjuvant icotinib for 12 months or 6 months following adjuvant chemotherapy improved DFS and OS compared with observation in patients with resected EGFR-mutated stage II-IIIA NSCLC with a manageable safety profile, supporting it as a potential treatment option.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 Kaplan-Meier estimates of DFS by the investigator in the ITT population. DFS disease-free survival, HR hazard ratio, CI confidence interval, ITT intention-to-treat

DFS_Kaplan-Meier_curve

DFS

Fig. 2 · Panel DFS_Kaplan-Meier_curve

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel DFS_Kaplan-Meier_curve 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 4

Fig. 4 Kaplan-Meier estimates of OS in the ITT population. OS, overall survival; HR, hazard ratio; CI, confidence interval; ITT, intention-to-treat

OS

overall survival

Fig. 4 · Panel OS

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel OS 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile. All randomized patients were included in the ITT population for efficacy analyses. Safety analyses were performed for all patients who received icotinib and those in the observation group. ITT, intention-to-treat; N number
非 KM Figure
Fig. 3Fig. 3 Forest plots of DFS by subgroup, according to investigator assessment. a Subgroup analyses of DFS for 12-month icotinib versus observation. b Subgroup analyses of DFS for 6-month icotinib versus observation. Subgroups were either pre-planned (sex, stage, and EGFR mutation type) or post hoc (age, smoking history, N stage, and side). DFS disease-free survival, HR hazard ratio, CI confidence interval, EGFR epidermal growth factor receptor
非 KM Figure